(Reuters) – Novavax Inc said on Tuesday that a mid-stage study of three of its vaccines, including a combination shot targeting COVID-19 and influenza, showed strong immune responses and were found to be safe.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Savio D’Souza)
